Xbiotech (XBIT) news
Recent news
Xbiotech announces election of Sushma Shivaswamy and Jan-Paul Simard as co-chief executive officers
XBiotech Inc. has announced the election of Sushma Shivaswamy and Jan-Paul Simard as co-chief executive officers, effective immediately. This leadership change marks a strategic shift for the biotechnology company as it continues to navigate its business and operational landscape. The decision…
AInvest Wire · Oct 23, 2026Xbiotech - Vilamakitug showed 62% reduction in risk of death in right-sided tumors
AInvest Wire · Oct 19, 2026Xbiotech - 44 of 79 patients (55.7%) in control arm alive at 12 months
XBiotech Inc. (NASDAQ: XBIT) has reported that 44 of 79 patients (55.7%) in the control arm of its clinical trial were alive at 12 months. This data point provides insight into the baseline survival rate for patients not receiving the experimental treatment, which is essential for evaluating the…
AInvest Wire · Oct 19, 2026Xbiotech - Announces positive final efficacy results from phase II taskin trial
Xbiotech recently announced the release of final efficacy results from its Phase II TASKIN trial, which evaluated the investigational monoclonal antibody Xilonix (anti-TNFα) in patients with severe sepsis and septic shock. The trial, conducted across multiple international sites, aimed to assess…
AInvest Wire · Oct 19, 2026Xbiotech Vilamakitug cuts death risk 62% in right-sided tumors
Xbiotech's Vilamakitug, an anti-IL1F1 monoclonal antibody, has demonstrated a significant reduction in mortality risk for patients with right-sided tumors, according to recent clinical findings. Specifically, the treatment was associated with a 62% decrease in the risk of death compared to…
AInvest Wire · Oct 19, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

